Based on the remarkable results of the AURA and FLAURA trials, osimertinib has been approved for the treatment of advanced NSCLC patients with EGFR mutations as first-line treatment and EGFR T790M-positive patients who had disease progression after prior-line EGFR-TKI treatment [4, 5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.